Community Financial Services Group LLC Trims Position in Pfizer Inc. $PFE

Community Financial Services Group LLC cut its position in Pfizer Inc. (NYSE:PFE) by 20.0% in the second quarter, HoldingsChannel.com reports. The firm owned 13,346 shares of the biopharmaceutical company’s stock after selling 3,341 shares during the quarter. Community Financial Services Group LLC’s holdings in Pfizer were worth $324,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter valued at $27,000. North Capital Inc. purchased a new position in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter valued at $28,000. Horizon Financial Services LLC purchased a new position in Pfizer during the first quarter valued at $35,000. Finally, WPG Advisers LLC purchased a new position in Pfizer during the first quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.29.

Pfizer Price Performance

Pfizer stock opened at $27.21 on Thursday. The firm has a 50-day moving average price of $24.59 and a 200-day moving average price of $24.14. The firm has a market capitalization of $154.68 billion, a PE ratio of 14.47, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.